APA (7th ed.) Citation

(2021). Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country.

Chicago Style (17th ed.) Citation

Cost-utility of Omalizumab for the Treatment of Uncontrolled Moderate-to-severe Persistent Pediatric Allergic Asthma in a Middle-income Country. 2021.

MLA (8th ed.) Citation

Cost-utility of Omalizumab for the Treatment of Uncontrolled Moderate-to-severe Persistent Pediatric Allergic Asthma in a Middle-income Country. 2021.

Warning: These citations may not always be 100% accurate.